FOIA to the Food and Drug Administration (FDA) seeking communications with companies developing vaccines or treatments for coronavirus.

FOIA to the Food and Drug Administration seeking communications regarding companies developing vaccines or treatments for coronavirus.

FOIA to the Food and Drug Administration (FDA) seeking records sufficient to identify the date Gilead submitted its request for orphan-drug designation for remdesivir as a treatment for COVID-19.

FOIA to the Food and Drug Administration seeking records sufficient to identify, with respect to requests for orphan-drug designation for treatments for COVID-19, the requester’s name, the date of the request, and the name of the treatment.

FOIA request to the Food and Drug Administration (FDA) seeking all decision memos, directives, policy interpretations, or guidance related to the coronavirus.

FOIA to the Department of Health and Human Services' (HHS) Food and Drug Administration (FDA) seeking records reflecting communications about the impact of decisions that affected the availability of coronavirus testing in the United States.

FOIA to the U.S. Food and Drug Administration (FDA) seeking emails sent by selected Centers for Disease Control and Prevention (CDC) officials to external entities involved in coronavirus testing and records reflecting any meetings with such entities.

FOIA to the Food and Drug Administration (FDA) seeking email communications sent by Timothy Stenzel, FDA Director of the Office of In Vitro Diagnostics and Radiological Health, to officials at the Centers for Disease Control and Prevention (CDC), during the period of his visit to a CDC facility working on tests for coronavirus.

The uncertainty and fear surrounding the coronavirus have laid bare the deadly consequences of President Donald Trump’s demand for obsequious loyalty and a refusal to take responsibility for mistakes.

No records response from the Food and Drug Administration regarding tests for asbestos in baby powder.